Product Name: Human DLL4 Antibody (Navicixizumab, Research Use)
Catalog Number: NBR-0163
Target Name: DLL4
Trade Name: Navicixizumab
Antibody Drug Description: Navicixizumab is an anti-DLL4/VEGF bispecific antibody product candidate that demonstrated antitumor activity in patients who were previously treated with Avastin® (bevacizumab) in a Phase 1b clinical trial. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: DLL4
Synonyms: Hdelta2; Delta; AOS6
Target Description: DLL4 (Delta Like Canonical Notch Ligand 4) is a Protein Coding gene. Diseases associated with DLL4 include Adams-Oliver Syndrome 6 and Adams-Oliver Syndrome. Among its related pathways are NOTCH2 Activation and Transmission of Signal to the Nucleus and Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants. Gene Ontology (GO) annotations related to this gene include calcium ion binding and Notch binding.
Ensembl: ENSG00000128917
Uniprot: Q9NR61